Elimination of cells deviated from human induced pluripotent stem cells with a photoactivatable IR700-labelled antibody.

Human induced pluripotent stem cells (hiPSCs) are important starting materials for cell therapy products (CTPs) used for transplantation. During cell culture, hiPSCs often spontaneously undergo morphological changes and lose pluripotency. Such cells are called 'deviated cells', which are deviated from the undifferentiated state of hiPSCs, lack the expression of hiPSC markers and become positive for the early differentiation marker SSEA1 (stage-specific embryonic antigen 1, Lewis X glycan). Previously, we identified fibronectin (FN) as a predominant carrier protein of SSEA1 secreted from deviated cells, but not hiPSCs. A sandwich assay using antibodies (Abs) against FN and SSEA1 was developed for non-destructive quantitative evaluation of deviated cells present in hiPSC cultures. In this study, a novel technology was developed to specifically eliminate deviated cells using an anti-FN Ab along with a near-infrared (NIR) photoabsorber, IRDye700DX N-hydroxysuccinimide ester (IR700), which has been used for cancer photoimmunotherapy. The anti-FN Ab conjugated with the IR700 dye (IR700-αFN) bound to and induced the death of deviated cells upon NIR irradiation. In contrast, IR700-αFN failed to stain the hiPSCs, and IR700-αFN/NIR had little or no effect on survival. Finally, IR700-αFN/NIR irradiation induced selective removal of deviated cells from a mixed culture with hiPSCs, demonstrating that the proposed method is suitable for the removal of unwanted deviated cells present in hiPSC culture for the production of CTPs.

Enhanced Sequence Coverage of Large Proteins by Combining Ultraviolet Photodissociation with Proton Transfer Reactions.

Ultraviolet photodissociation (UVPD) produces rich and informative fragmentation of intact protein ions, but in the case of high mass proteins (>30 kDa) the spectra are congested with overlapping isotope patterns of highly charged fragment ions. In the most congested regions, many fragments cannot be confidently identified even when high-resolution mass analyzers and modern deconvolution algorithms are used. Gas-phase ion-ion proton transfer reactions (PTR), which reduce the charge states of highly charged ions, can be used to alleviate this congestion and facilitate the identification of additional fragment ions when performed following UVPD. We have developed protocols for sequentially performing PTR on multiple populations of ions generated by UVPD in a way that can be tailored to balance the depth of characterization with speed and throughput. The improvements in sequence coverage and fragment identifications are demonstrated for four proteins ranging in size from 29 to 56 kDa. Sequence coverages up to 80% were achieved for carbonic anhydrase (29 kDa), 50% for aldolase (39 kDa), 46% for enolase (46 kDa), and 27% for glutamate dehydrogenase (56 kDa), and up to 74% sequence coverage was obtained for 25 kDa antibody drug conjugate subunits in online LC-MS experiments.

Near-Infrared Photoimmunotherapy of Cancer.

This Account is the first comprehensive review article on the newly developed, photochemistry-based cancer therapy near-infrared (NIR) photoimmunotherapy (PIT). NIR-PIT is a molecularly targeted phototherapy for cancer that is based on injecting a conjugate of a near-infrared, water-soluble, silicon-phthalocyanine derivative, IRdye700DX (IR700), and a monoclonal antibody (mAb) that targets an expressed antigen on the cancer cell surface. Subsequent local exposure to NIR light turns on this photochemical "death" switch, resulting in the rapid and highly selective immunogenic cell death (ICD) of targeted cancer cells. ICD occurs as early as 1 min after exposure to NIR light and results in irreversible morphologic changes only in target-expressing cells based on the newly discovered photoinduced ligand release reaction that induces physical changes on conjugated antibody/antigen complex resulting in functional damage on cell membrane. Meanwhile, immediately adjacent receptor-negative cells are totally unharmed. Because of its highly targeted nature, NIR-PIT carries few side effects and healing is rapid. Evaluation of the tumor microenvironment reveals that ICD induced by NIR-PIT results in rapid maturation of immature dendritic cells adjacent to dying cancer cells initiating a host anticancer immune response, resulting in repriming of polyclonal CD8+T cells against various released cancer antigens, which amplifies the therapeutic effect of NIR-PIT. NIR-PIT can target and treat virtually any cell surface antigens including cancer stem cell markers, that is, CD44 and CD133. A first-in-human phase 1/2 clinical trial of NIR-PIT using cetuximab-IR700 (RM1929) targeting EGFR in inoperable recurrent head and neck cancer patients successfully concluded in 2017 and led to "fast tracking" by the FDA and a phase 3 trial ( https://clinicaltrials.gov/ct2/show/NCT03769506 ) that is currently underway in 3 countries in Asia, US/Canada, and 4 countries in EU. The next step for NIR-PIT is to further exploit the immune response. Preclinical research in animals with intact immune systems has shown that NIT-PIT targeting of immunosuppressor cells within the tumor, such as regulatory T-cells, can further enhance tumor-cell-selective systemic host-immunity leading to significant responses in distant metastatic tumors, which are not treated with light. By combining cancer-targeting NIR-PIT and immune-activating NIR-PIT or other cancer immunotherapies, NIR-PIT of a local tumor, could lead to responses in distant metastases and may also inhibit recurrences due to activation of systemic anticancer immunity and long-term immune memory without the systemic autoimmune adverse effects often associated with immune checkpoint inhibitors. Furthermore, NIR-PIT also enhances nanodrug delivery into tumors up to 24-fold superior to untreated tumors with conventional EPR effects by intensively damaging cancer cells behind tumor vessels. We conclude by describing future advances in this novel photochemical cancer therapy that are likely to further enhance the efficacy of NIR-PIT.

A ratiometric photoelectrochemical immunosensor based on g-C3N4@TiO2 NTs amplified by signal antibodies-Co3O4 nanoparticle conjugates.

Herein, we report a ratiometric photoelectrochemical (PEC) immunosensor coupled with secondary antibodies-Co3O4 nanoparticle conjugates (Ab2-Co3O4 NPs) for signal amplification. The Ab1-g-C3N4@TiO2 NTs and BSA-g-C3N4@TiO2 NTs act as the sensing and reference photoelectrodes, where Ab1, BSA and TiO2 NTs are the capture antibodies, bovine serum albumin and TiO2 nanotube arrays, respectively. In the presence of target Ag, the sensing PEC photocurrent decreases due to the steric hindrance of Ab1 molecules, which increases the inner resistance of the photoelectrode. The signal-off response is enhanced further using Ab2-Co3O4 NP conjugates due to their steric hindrance effect and the consumption of electron donors by the Co3O4 NPs. Furthermore, the performance of the ratiometric PEC platform is tested using alpha-fetoprotein (AFP) as a model antigen. Under the optimal conditions, the concentration of AFP is detected in the range of 0.4 pg mL-1 to 40 ng mL-1 with a detection limit of 0.2 pg mL-1. This ratiometric strategy is beneficial to improve the reliability and anti-interference ability of PEC immunosensors.